智通财经网·2026-01-21 23:25Core Viewpoint - The recent issuance of the "Guidelines for the Establishment of Price Projects for Surgical and Treatment Auxiliary Operations" by the National Medical Insurance Administration is expected to reshape industry valuation logic, favoring platform companies backed by large medical groups that can adapt to new insurance payment rules and possess funding and channel advantages [1] Group 1: Industry Trends - The domestic surgical robot industry, which has started relatively late, has been dominated by foreign brands. However, the release of the "Guidelines" and the continuation of policies promoting large-scale equipment updates are expected to accelerate the penetration rate of surgical robots, with strong certainty for domestic replacements [2] - As an example, the market share of the Da Vinci surgical robot is gradually being reshaped due to the release of production capacity by leading domestic companies and the maturity of clinical data verification. By 2025, domestic brands are projected to surpass imported brands in the bidding volume for laparoscopic surgical robots [2] Group 2: Market Recovery and Equipment Updates - The industry is gradually recovering from the impact of anti-corruption measures, with the issuance of large medical equipment configuration certificates entering a final sprint phase. For laparoscopic surgical robots, the total number of bids is expected to reach 110 units in 2025, compared to approximately 98 units in 2024, driven by concentrated execution of the "14th Five-Year" quota and equipment update subsidies [3] - The upcoming "15th Five-Year" configuration certificate management is expected to be more flexible, with an increase in the variety of approved domestic models, suggesting that the high demand for industry bidding and installation will continue into 2026 [3] Group 3: Business Logic Restructuring - The "Guidelines" categorize surgical robot auxiliary operations by function and include essential consumables in the pricing structure. This policy is anticipated to reshape industry valuation logic, favoring platform companies with strong financial and channel advantages and innovative domestic companies that meet high pricing standards [4] - Companies with differentiated innovation capabilities, such as single-port and 5G remote surgery, are expected to steadily increase market share and profitability through service fee models [4]